Diagnostics

Robinhood's new premium card bundles stock trading with blood tests. We explore the new frontier where fintech meets health tech and what it means for you.

As a deadly Ebola outbreak grips Central Africa, OraSure's new 30-minute test offers a critical lifeline, empowering frontline workers without labs or power.

After a major restructure, Mauna Kea Technologies posts 44% growth, fueled by its Cellvizio imaging platform and a clever cash-pay model for global expansion.

As the diagnostics market booms, DCN Dx hires veteran Trevor Brown to unify its services, aiming to become the go-to partner for derisking IVD commercialization.

The life sciences giant beat expectations with a 60% earnings jump, raising its 2026 forecast. Key drivers include the Masimo deal and a new acquisition plan.

New VA data reveals a shocking rise in veteran traumatic brain injuries. As advocates demand action, the true scale of this invisible wound remains unknown.

Shelf-stable donor milk pioneer Leche and testing firm Tiny Health launch a study to see if a little breast milk can make a big difference for formula-fed babies.

A single-collimator system that images all isotopes is more than an upgrade; it's a strategic move to dominate the future of personalized cancer care.

IntelliGenome's revolutionary CRISPR-TB diagnostic arrives in South Africa via a key partnership, offering a new, blood-based tool to tackle the TB crisis.

Bracco Imaging's elite EcoVadis score isn't just a sustainability win. It's a blueprint for execution, reshaping supply chains and building real competitive advantage.

Aptorum Group is transforming into Niki BioSolutions after its merger with DiamiR, betting its future on innovative microRNA blood tests for brain health.

EHE Health is now offering GRAIL's Galleri test, a move that signals a major shift in corporate wellness but raises key questions about cost and access.

SpotitEarly's novel platform combines trained dogs and machine learning for non-invasive cancer detection. A new partnership aims to bring it to market by 2027.

A new biotech collaboration aims to accelerate a novel diagnostic platform, highlighting a growing trend of outsourcing operations to speed innovation in precision medicine.

A Tennessee insurer's policy update on liver diagnostics is more than a clinical decision—it's a masterclass in market control and a stark warning to innovators.

Health tech firm Ash adds Jon Stout and Matt Benton, who scaled AbleTo to a $470M acquisition, to conquer the competitive Medicare Advantage market.

Bruker's acquisition of the DISQVER® platform signals a major shift in infection diagnostics, promising to identify thousands of pathogens in hours, not days.

With a new one-hour test for deadly bloodstream infections, QIAGEN aims to arm clinicians in the fight against sepsis and antimicrobial resistance.

A new MTEC initiative aims to build on-demand diagnostic labs and autonomous ventilators, pushing the boundaries of battlefield medicine and technology's dual use.

The launch of LacP™ isn't just a new test; it's a strategic move into the high-growth femtech diagnostics space, shifting the focus from reaction to prevention.